share_log

NexImmune | 8-K: Current report

SEC announcement ·  Feb 2 13:31
Summary by Moomoo AI
NexImmune, Inc. has mutually agreed with Cantor Fitzgerald & Co. and BTIG, LLC to terminate their Controlled Equity Offering SM Sales Agreement and the associated 'at the market' offering program (ATM Program) as of February 2, 2024. The agreement, initially disclosed in June 2022, allowed NexImmune to sell shares of its common stock up to an aggregate offering price of $50,000,000. Before the termination, NexImmune successfully sold 127,396 shares, resulting in net proceeds of approximately $5.1 million. The termination of the Sales Agreement and ATM Program does not involve any material early termination penalties for the company. Further details of the Sales Agreement were referenced in the Form 8-K filed with the SEC on June 17, 2022.
NexImmune, Inc. has mutually agreed with Cantor Fitzgerald & Co. and BTIG, LLC to terminate their Controlled Equity Offering SM Sales Agreement and the associated 'at the market' offering program (ATM Program) as of February 2, 2024. The agreement, initially disclosed in June 2022, allowed NexImmune to sell shares of its common stock up to an aggregate offering price of $50,000,000. Before the termination, NexImmune successfully sold 127,396 shares, resulting in net proceeds of approximately $5.1 million. The termination of the Sales Agreement and ATM Program does not involve any material early termination penalties for the company. Further details of the Sales Agreement were referenced in the Form 8-K filed with the SEC on June 17, 2022.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more